| Literature DB >> 25087979 |
Annie M Tremblay1, Edoardo Missiaglia2, Giorgio G Galli1, Simone Hettmer3, Roby Urcia4, Matteo Carrara5, Robert N Judson6, Khin Thway7, Gema Nadal4, Joanna L Selfe8, Graeme Murray9, Raffaele A Calogero5, Cosimo De Bari9, Peter S Zammit10, Mauro Delorenzi11, Amy J Wagers12, Janet Shipley8, Henning Wackerhage4, Fernando D Camargo13.
Abstract
The role of the Hippo pathway effector YAP1 in soft tissue sarcomas is poorly defined. Here we report that YAP1 activity is elevated in human embryonal rhabdomyosarcoma (ERMS). In mice, sustained YAP1 hyperactivity in activated, but not quiescent, satellite cells induces ERMS with high penetrance and short latency. Via its transcriptional program with TEAD1, YAP1 directly regulates several major hallmarks of ERMS. YAP1-TEAD1 upregulate pro-proliferative and oncogenic genes and maintain the ERMS differentiation block by interfering with MYOD1 and MEF2 pro-differentiation activities. Normalization of YAP1 expression reduces tumor burden in human ERMS xenografts and allows YAP1-driven ERMS to differentiate in situ. Collectively, our results identify YAP1 as a potent ERMS oncogenic driver and a promising target for differentiation therapy.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25087979 DOI: 10.1016/j.ccr.2014.05.029
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743